Tags: biogen | elan | ms | drug

Biogen Pays Elan $3.25 Billion to Take Over MS Drug

Wednesday, 06 Feb 2013 07:57 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp. PLC in exchange for a $3.25 billion cash payment and royalties on future sales.

The drug developers currently split earnings from Tysabri, but Elan said the new deal will give it capital for investing and growing its business.

Under the new terms, Elan will receive a royalty of 12 percent of global Tysabri sales for the first 12 months. It will then receive a royalty of 18 percent on up to $2 billion of global sales and 25 percent on more than $2 billion.

The boards of both companies have approved the deal, which is expected to close by the end of the second quarter.

Biogen Idec Inc., based in Weston, Mass., expects the deal to add between 20 cents and 30 cents to its 2013 earnings per share.

Tysabri a form of multiple sclerosis that cycles between stages of relapse and remission.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
You May Also Like
Around the Web

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved